Siemens ADVIA Centaur BR assay Cat No. 03896216, SMN 10334837 (5-pack/250 tests) BR Assay for CA 27.29 The ADVIA Centaur® BR assay is an in vitro diagnostic test for the quantitative serial determination of cancer antigen CA 27.29 in human serum using the ADVIA Centaur®, ADVIA Centaur® XP, and ADVIA Centaur® XPT systems. The test is intended for use as an aid in monitoring patients previously treated for Stage II or Stage III breast cancer. Serial testing for CA 27.29 in the serum of patients who are clinically free of disease should be used in conjunction with other clinical methods used for the early detection of cancer recurrence. The test is also intended for use as an aid in the management of breast cancer patients with metastatic disease by monitoring the progression or regression of disease in response to treatment.
Published April 12, 2017 · Recall initiated: March 8, 2017
Summary
FDA records medical device Class II recall Z-1748-2017, published April 12, 2017 and initiated March 8, 2017. Recalling firm: Siemens Healthcare Diagnostics, Inc; Status: Terminated; Reported quantity: 1900 kits; Lot: All lot codes. Class II means possible temporary or medically reversible effects, or a remote probability of serious health consequences.
Status when published: Terminated — openFDA updates weekly, so this field may not reflect the current status. Always confirm with the official notice.
What's the hazard
Potential for the ADVIA Centaur Syphilis assay to interfere with the BR (CA 27.29) a assay on the ADVIA Centaur Systems
What to do
Voluntary: Firm initiated · Letter
Get an email when a new FDA recall like this is published
Free. We only write when there's a new recall that matches. Unsubscribe in one click.
Recall details
- Manufacturer
- Siemens Healthcare Diagnostics, Inc
- Distributor
- Worldwide Distribution - US (Nationwide) Internationally to Australia, Brazil, Canada, Columbia, Cyprus, Japan, Spain
- Lot
- All lot codes
- Risk classification
- Class II
- Area (FDA)
- device
- Country
- United States
Related recalls
- FDASiemens ADVIA Centaur Folate 100 test kit-for IVD of folate in serum or red blood cells SMN:10310308January 29, 2020
- FDASiemensADVIA Centaur aTG (500 test kit) Siemens Material Number (SMN): 10492399May 8, 2019
- FDAAtellica IM aTG (500 test kit) Siemens Material Number (SMN): 10995462May 8, 2019
- FDASiemens Atellica IM aTG (100 test kit) Siemens Material Number (SMN): 10995461May 8, 2019
- FDABD Vacutainer Buffered Sodium Citrate: (9NC) Blood Collection Tubes, 4.5 mL, 13 x 75 mm, Mfd: Becton DickinsonApril 12, 2017
- FDABrightView XCT model number 882482 BrightView and BrightView X are gamma cameras designed for single or dualApril 12, 2017
Questions about this recall
Was Siemens ADVIA Centaur BR assay Cat No. 03896216, SMN 10334837 (5-pack/250 tests) BR Assay for CA 27.29 The ADVIA Centaur® BR assay is an in vitro diagnostic test for the quantitative serial determination of cancer antigen CA 27.29 in human serum using the ADVIA Centaur®, ADVIA Centaur® XP, and ADVIA Centaur® XPT systems. The test is intended for use as an aid in monitoring patients previously treated for Stage II or Stage III breast cancer. Serial testing for CA 27.29 in the serum of patients who are clinically free of disease should be used in conjunction with other clinical methods used for the early detection of cancer recurrence. The test is also intended for use as an aid in the management of breast cancer patients with metastatic disease by monitoring the progression or regression of disease in response to treatment. recalled?
Yes. FDA published recall Z-1748-2017 on April 12, 2017. Reported hazard: Potential for the ADVIA Centaur Syphilis assay to interfere with the BR (CA 27.29) a assay on the ADVIA Centaur Systems
What should I do if I have this product?
Voluntary: Firm initiated · Letter